Japan Specialist

Mark Chadwick

Over 20 years experience in equities and asset management in Asia and Japan. Qualified CFA with experience analyzing companies as a buy-side analyst. In-depth knowledge of company fundamental analysis, corporate governance and valuations.

TOPIX Inclusion: Pharma Foods Int'l (2929 JP) - Stupendous Revenue Growth Vs Ridiculous Volume/Float

Equity Bottom-Up

Pharma Foods International / Equity Bottom-Up

<ul>
<li>Pharma Foods has enjoyed 45% compound annual sales growth over the past five years. </li>
<li>This fiscal year, the company is guiding for sales to grow 160% to ¥40bn. </li>
<li>Growth is being driven by, Newmo, a hair growth product.</li>
<li>Longer-term, the tie-up with Mitsubishi Tanabe highlights the potential of the bio-tech pipeline. </li>
<li>TSE First Section inclusion and the stand-out growth metrics could see the stock attract a more institutional following.</li>
</ul>


Pharma Foods has enjoyed 45% compound annual sales growth over the past five years. 
This fiscal year, the company is guiding for sales to grow 160% to ¥40bn. 
Growth is being driven by, Newmo, a hair growth product.
Longer-term, the tie-up with Mitsubishi Tanabe highlights the potential of the bio-tech pipeline. 
TSE First Section inclusion and the stand-out growth metrics could see the stock attract a more institutional following.


Japan Small Cap Growth: Pharma Foods - Hair Growth = Stock Growth